T. Rowe Price Associates’s Protalix BioTherapeutics PLX Stock Holding History

T. Rowe Price Associates’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$117K	Buy	53,478 +18,200	+52%	+$45.2K	﹤0.01%	2967
2025 Q4	$64K	Hold	35,278	–	–	﹤0.01%	3009
2025 Q3	$79K	Hold	35,278	–	–	﹤0.01%	2962
2025 Q2	$53K	Buy	+35,278	New	+$72.2K	﹤0.01%	3000
2024 Q2	–	Sell	-15,982	Closed	-$21K	–	3002
2024 Q1	$21K	Hold	15,982	–	–	﹤0.01%	2927
2023 Q4	$29K	Hold	15,982	–	–	﹤0.01%	2855
2023 Q3	$27K	Buy	15,982 +4,535	+40%	+$8.14K	﹤0.01%	2838
2023 Q2	$23K	Buy	+11,447	New	+$27.3K	﹤0.01%	2861

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

T. Rowe Price Associates's PLX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Protalix BioTherapeutics (PLX) stake by 52% in Q1 2026, buying an estimated $45.2K and bringing the position to 53,478 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #2967.

T. Rowe Price Associates first reported a position in PLX in Q2 2023 and has held it in 8 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

T. Rowe Price Associates held 53,478 shares of Protalix BioTherapeutics worth $117K as of Q1 2026.
T. Rowe Price Associates bought 18,200 Protalix BioTherapeutics shares in Q1 2026, an estimated $45.2K.
Protalix BioTherapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2967 holding.
T. Rowe Price Associates first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 8 quarters since.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.